甲磺酸阿帕替尼治疗进展性碘难治性甲状腺癌的短期疗效及安全性初步报告

林岩松; 王　宸; 李　慧

doi:10.19401/j.cnki.1007-3639.2016.09.001

您当前的位置：

首页 >

文章列表页 >

甲磺酸阿帕替尼治疗进展性碘难治性甲状腺癌的短期疗效及安全性初步报告

更新时间：2025-12-31

- 甲磺酸阿帕替尼治疗进展性碘难治性甲状腺癌的短期疗效及安全性初步报告
- The preliminary report about the efficacy and safety evaluation of apatinib in progressive radioactive iodine-refractory differentiated thyroid cancer within 8 weeks
- 中国癌症杂志 2016年26卷第9期页码：721-726
- 作者机构：
  
  中国医学科学院北京协和医学院核医学科,北京,100730
- 作者简介：
- 基金信息：
  
  国家自然科学基金(81571714)。
- DOI：10.19401/j.cnki.1007-3639.2016.09.001
  中图分类号：
- 网络出版：2016-10-26，
  
  纸质出版：2016-10-26
- 稿件说明：
移动端阅览
林岩松,王　宸,李　慧,等. 甲磺酸阿帕替尼治疗进展性碘难治性甲状腺癌的短期疗效及安全性初步报告[J]. 中国癌症杂志, 2016, 26(9): 721-726.

林岩松, 王　宸, 李　慧. The preliminary report about the efficacy and safety evaluation of apatinib in progressive radioactive iodine-refractory differentiated thyroid cancer within 8 weeks[J]. China Oncology, 2016, 26(9): 721-726.
林岩松,王　宸,李　慧,等. 甲磺酸阿帕替尼治疗进展性碘难治性甲状腺癌的短期疗效及安全性初步报告[J]. 中国癌症杂志, 2016, 26(9): 721-726. DOI： 10.19401/j.cnki.1007-3639.2016.09.001.

林岩松, 王　宸, 李　慧. The preliminary report about the efficacy and safety evaluation of apatinib in progressive radioactive iodine-refractory differentiated thyroid cancer within 8 weeks[J]. China Oncology, 2016, 26(9): 721-726. DOI： 10.19401/j.cnki.1007-3639.2016.09.001.

摘要

背景与目的：碘难治性甲状腺癌(radioactive iodine-refractory differentiated thyroid cancer，RAIRDTC)是目前临床诊疗的难点与热点，目前国际指南中推荐的靶向治疗药物仅有索拉非尼及乐伐替尼。该研究报告具有我国自主知识产权的靶向药物甲磺酸阿帕替尼治疗进展性碘RAIR-DTC 8周后的短期疗效及安全性。方法：纳入10例进展性RAIR-DTC患者予阿帕替尼治疗(750 mg，每天1次，口服)。每2周复查甲状腺球蛋白(thyroglobulin，Tg)，每4周CT监测靶病灶(target lesions，TL)。观察甲状腺癌血清标志物Tg水平变化，采用实体瘤疗效评价标准1.1(response evaluation criteria in solid tumors，RECIST 1.1)评估疗效。初步评估患者经药物治疗的短期不良事件(adverse event，AE)以评估安全性。结果：8例Tg可评价的患者，在治疗2周后Tg即出现下降，在治疗8周后较基线平均降幅达68%，达到“生化部分缓解”。10例患者共18个TL，治疗4周后即出现缩小，在8周后较基线平均缩小达40％，9例患者(9/10，90%)达到部分缓解，1例(1/10，10%)呈疾病稳定，客观缓解率及疾病控制率分别达90%和100%。最常见的3级以上AE主要包括手足皮肤反应、高血压和低钙血症，分别占50%、30%和20%，未观察到与药物相关的严重AE。结论：甲磺酸阿帕替尼可安全用于RAIR-DTC治疗，且在8周治疗中从血清学及结构影像学角度证实快速有效，客观缓解率高。

Abstract

Background and purpose: Radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC) is a big challenge in the management of thyroid cancer. Sorafenib and lenvatinib are the 2 tyrosine kinase inhibitors (TKIs) recently approved by FDA

which could not be affordable for most of the Chinese patients. This pilot study aimed to evaluate the short term efficacy and safety of apatinib

a Chinese domestic TKI targeted vascular endothelial growth factor receptor (VEGFR)

in advanced RAIR-DTC. Methods: Ten patients who were identified as progressive RAIR-DTC were enrolled in this study. Patients received oral apatinib 750 mg once daily. Both thyroglobulin (Tg) and/or Tg antibody (TgAb) levels were monitored every 2 weeks after the treatment. Computed tomography (CT) was performed every 4 weeks after apatinib treatment to evaluate the response according to response evaluation criteria in solid tumor version 1.1 (RECIST 1.1). Within 8 weeks after apatinib treatment

therapeutic response was evaluated in terms of Tg

a sensitive biochemical tumor marker for DTC

and RECIST 1.1 assessment. Meanwhile

the adverse events (AE) were monitored during the therapy. Results: The Tg levels declined after the first 2 weeks of apatinib treatment

and a mean decline rate of 68% could be observed in 8 patients with Tg available for evaluation after 8 weeks

which repre-sented a biochemical partial response. Eighteen target lesions (TL) of 10 patients were evaluated and followed up. The diameter of TL began to decrease after 4 weeks

and a mean decline of 40% could be observed after 8 weeks’ apatinib treatment. A total of 9 patients (9/10) achieved partial response according to RECIST 1.1 criteria and 1 patient with stable disease

with 90% objective response rate and 100% disease control rate. The most common AE beyond grade 3 included hand-foot-skin reactions

hypertension and hypocalcemia

which accounted for 50%

30% and 20% of the cases

respectively. No severe AE related to apatinib was observed during the treatment. Conclusion: A safe and rapid response and high partial response rate in terms of biochemistry

RECIST 1.1 could be observed in RAIR-DTC patients within 8 weeks of apatinib treatment.

关键词

Keywords

references

浏览量

2473

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

碘-125粒子植入治疗碘难治性分化型甲状腺癌淋巴结转移灶的临床研究

颈部超声联合血清甲状腺球蛋白评估阿帕替尼治疗进展性碘难治性分化型甲状腺癌的短期疗效

¹⁸F-FDG PET/CT在阿帕替尼治疗肺多发转移性碘难治性分化型甲状腺癌评估中的价值

阿帕替尼治疗晚期胃癌的疗效预测和预后分析